Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1948]
News [3627]
Articles [95]
Editorials [5]
Conferences [157]
elearning [19]
ASH 2021: Bispecific antibody mosunetuzumab brings deep remission for follicular lymphoma
ASH 2021: Bispecific antibody mosunetuzumab brings deep remission for follicular lymphoma
ASH 2021: Axicabtagene ciloleucel shows durable responses after two years for patients with indolent non-Hodgkin lymphoma
ASH 2021: Axicabtagene ciloleucel shows durable responses after two years for patients with indolent non-Hodgkin...
ASH 2021: Axicabtagene ciloleucel demonstrates potential as first-line therapy for patients with high-risk large B-cell lymphoma
ASH 2021: Axicabtagene ciloleucel demonstrates potential as first-line therapy for patients with high-risk large B...
ASH 2021: Immune-boosting antibody treatment isatuximab meets primary endpoint for multiple myeloma
ASH 2021: Immune-boosting antibody treatment isatuximab meets primary endpoint for multiple myeloma
ASH 2021: ZUMA-7 demonstrates lasting benefits of CAR-T therapy over current standard of care for large B-cell lymphoma
ASH 2021: ZUMA-7 demonstrates lasting benefits of CAR-T therapy over current standard of care for large B-cell...
SABCS 2021: Subgroup analysis of trastuzumab deruxtecan shows ‘encouraging’ results in controlling stable brain metastases in HER2-positive metastatic breast cancer
SABCS 2021: Subgroup analysis of trastuzumab deruxtecan shows ‘encouraging’ results in controlling stable brain...
Moderate immune response is more effective against leukaemia
Moderate immune response is more effective against leukaemia
In breast cancer, the best defence is a strong offence
In breast cancer, the best defence is a strong offence
Chemoimmunotherapy dramatically improved survival of high-risk neuroblastoma patients
Chemoimmunotherapy dramatically improved survival of high-risk neuroblastoma patients
Which glioblastoma patients will respond to immunotherapy?
Which glioblastoma patients will respond to immunotherapy?

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation